Aller au contenu principal

Billets de Michelle Dawson

Billet publié sur Twitter/X le 28/08/2013 19:03

Twitter/X Essai clinique clinicaltrials.gov Extrait cité dans le billet Lien intégré au billet Termes sur l’autisme

Liens cités structurés

1 ressource citée

Essai clinique Récupéré Publication clinicaltrials.gov

Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (2013). Rapalogues for Autism Phenotype in TSC: A Feasibility Study. ClinicalTrials.gov. Hugo W. Moser Research Institute at Kennedy Krieger, Inc..

Date de publication
2013
Identifiant
NCT01929642
Auteurs
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Source de métadonnées
clinicaltrials.gov

Résumé

The purpose of this study is to assess the feasibility and safety of administering rapalogues, sirolimus or everolimus, in participants with Tuberous Sclerosis Complex (TSC) and self-injury and to measure cognitive and behavioral changes, including reduction in autistic symptoms, self-injurious and aggressive behaviors, as well as improvements in cognition across multiple domains of cognitive function.